2015•LeukemiaRequires access

Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy

Nico Lachmann, K Czarnecki, Sebastian Brennig, Ruhi Phaltane, Melina Heise, Niels Heinz, Henning Kempf, Dagmar Dilloo, Volkhard Kaever, Axel Schambach, Michael Heuser, Thomas Moritz

Open publisher page 9 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Cladribine, Deoxycytidine kinase, Cytarabine, Fludarabine, Deoxycytidine, Context (archaeology), Antimetabolite, Medicine

Back to paper search Browse research topics Original source

Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy — Research Paper | ScholarLens